Compare IRON & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | SAM |
|---|---|---|
| Founded | 2017 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2020 | 1996 |
| Metric | IRON | SAM |
|---|---|---|
| Price | $70.54 | $236.65 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 11 |
| Target Price | $103.18 | ★ $229.70 |
| AVG Volume (30 Days) | ★ 356.5K | 139.1K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 95.45 |
| EPS | N/A | ★ 9.89 |
| Revenue | N/A | ★ $1,964,994,000.00 |
| Revenue This Year | N/A | $0.97 |
| Revenue Next Year | $283.52 | $1.36 |
| P/E Ratio | ★ N/A | $24.52 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $39.20 | $186.72 |
| 52 Week High | $99.50 | $264.46 |
| Indicator | IRON | SAM |
|---|---|---|
| Relative Strength Index (RSI) | 64.18 | 49.71 |
| Support Level | $57.79 | $211.05 |
| Resistance Level | $82.70 | $240.36 |
| Average True Range (ATR) | 2.83 | 8.62 |
| MACD | 1.07 | 0.84 |
| Stochastic Oscillator | 96.13 | 44.35 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.